An observational study in Survival, sponsored by Kun-Ming Rau. Completed at 5 sites in Taiwan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Kun-Ming Rau · Observational
Astragalus polysaccharides (APS), acting as an immunomodulator, is known to modulate the tumor microenvironment and inhibit tumor growth and progression, thereby suggesting potential as an adjuvant cancer therapy to improve treatment outcomes.
PG2 (APS Injection) has completed a clinical trial (Protocol name: PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance with Chemotherapy among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy , NCT03314805, hereinafter called the parent trial) aimed to show that PG2 treatment among stage II/III breast patients under adjuvant Epirubicin and cyclophosphamide (EC) regimen in reduction of chemotherapy-induced toxicities and encouraging compliance with chemotherapy. This study will further explore whether the addition of PG2 can delay cancer recurrence or metastasis, thereby conferring substantial survival benefits for early breast cancer patients with adjuvant chemotherapy by retrospectively collecting recurrence, metastasis, and survival information from patients enrolled in the parent trial.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 66 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →This is the only study on the registry with Kun-Ming Rau as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients who were previously enrolled in the [PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance with Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy/NCT03314805] study.
Exclusion Criteria:
Astragalus polysaccharides 500 mg
Drug: Astragalus polysaccharides 500 mg
Placebo
Drug: Placebo
Adjuvant chemotherapy in combination with PG2
Also known as: PG2 Lyo. Injection 500 mg
Adjuvant chemotherapy in combination with Placebo
Distant metastasis-free survival
Time from random assignment to any first event of distant recurrence, death from any cause, or second (non-breast) invasive cancer.
Time frame: from random assignment to Aug 27, 2025
Disease-free survival
Time from random assignment to any first event of invasive ipsilateral or contralateral breast recurrence, local or regional invasive recurrence, distant recurrence, second (non-breast) invasive cancer, or death from any cause.
Time frame: from random assignment to Aug 27, 2025
Overall Survival
Time from random assignment until death from any cause.
Time frame: from random assignment to Aug 27, 2025
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.